Table 1 Demographics and clinical characteristics of patients with axial SpA

Sex (n, f/m)

13/42

Age, median (range) years

50.4 (21.7–66.0)

HLA-B27 positive (n, %)

47 (85.5)

Duration of symptoms, median (range) years

20.0 (3.6–49.0)

Time since diagnosis, mean (S.D.) years

14.9 (10.2)

BASDAI, median (range)

2.5 (0.0–6.5)

BASFI, mean (S.D.)

2.4 (1.6)

BASMI, median (range)

2.6 (0.3–6.4)

ASDAS-CRP, mean (S.D.)

1.8 (0.7)

CRP, mean (S.D.) mg/l^*

4.0 (5.0)

Patients on TNF-inhibitors n (%)

33 (60.0)

Patients on IL-17-inhibitors n (%)

3 (5.5)

Patients on JAK-inhibitors n (%)

1 (0.2)

Patients on continuous NSAID-therapy n (%)

8 (14.6)